Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease

Renal Failure

Volumn 29, Issue 1, 2007, Pages 55-59

  Namli, Sule ^a   Oflaz, Hüseyin ^a   Turgut, Faruk ^a   Alisir, Sabahat ^a   Tufan, Fatih ^a   Ucar, Adem ^a   Mercanoglu, Fehmi ^a   Ecder, Tevfik ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Autosomal dominant polycystic kidney disease; Endothelial dependent dilatation; Endothelial dysfunction; Simvastatin

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; SIMVASTATIN;

ADULT; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPEREMIA; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MALE; PRIORITY JOURNAL; TREATMENT DURATION; VASODILATATION;

ADULT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIMVASTATIN;

EID: 33846975801     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220601038892     Document Type: Article

References (30)

1. Fick-Brosnahan GM, Ecder T, Schrier R: Polycystic kidney disease, in Schrier RW Ed. Diseases of the Kidney and Urinary Tract (7th edn). Philadelphia, Lippincott Williams & Wilkins, 2001; 547-88.
2. Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5:2048-2056.
3. Wang D, Iversen J, Wilcox CS, Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003;64:1381-1388.
4. Kocaman O, Oflaz H, Yekeler E, Dursun M, Erdogan D, Demirel S, Alisir S, Turgut F, Mercanoglu F, Ecder T. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004;43:854-860.
5. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-1131.
6. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
7. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104:376-379.
8. Dogra GK, Watts GF, Herrmann S, Thomas MAB, Irish AB. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 2002;62:550-557.
9. van Dijk MA, Kamper AM, van Veen S, Souverijn JHM, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16:2152-2157.
10. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994;343:824-827.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
12. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340: 1111-1115.
13. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997;8:1292-1297.
14. Saggar-Malik AK, Missouris CG, Gill JS, Singer DR, Markandu ND, MacGregor NA. Left ventricular mass in normotensive subjects with autosomal dominant polycystic kidney disease. BMJ 1994;309:1617-1618.
15. Bardaji A, Martinez-Vea A, Gutierrez C, Ridao C, Richart C, Oliver JA. Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998;32: 970-975.
16. Zeier M, Geberth S, Schmidf KG, Mandelbaum A, Ritz E. Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993;3: 1451-1457.
17. Valero FA, Martinez-Vea A, Bardaji A, Gutierrez C, Garcia C, Richart C, Oliver JA. Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999;10:1020-1026.
18. Oflaz H, Alisir S, Buyukaydin B, Kocaman O, Turgut F, Namli S, Pamukcu B, Oncul A, Ecder T. Biventricular diastolic dysfunction in patients with autosomal dominant polycystic kidney disease. Kidney Int 2005;68:2244-2249.
19. Martinez-Vea A, Bardaji A, Gutierrez C, Garca C, Peralta C, Marcas L, Oliver JA. Exercise blood pressure, cardiac structure, and diastolic dysfunction in young normotensive patients with polycystic kidney disease: A prehypertensive state. Am J Kidney Dis 2004;44:216-223.
20. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-1241.
21. Al-Nimri MA, Komers R, Oyama TT, Subramanya AR, Lindsley JN, Anderson S. Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003;63:1776-1784.
22. Devuyst O, Persu A, Vo-Cong M-T. Autosomal dominant polycystic kidney disease: modifier genes and endothelial dysfunction. Nephrol Dial Transplant 2003;18:2211-2215.
23. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002;86:5-18.
24. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-428.
25. Marz W, Koenig W. HMG-CoA reductase inhibition: antiinflammatory effects beyond lipid lowering? J Cardiovasc Risk 2003;10:169-179.
26. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003;91:4B-8B.
27. Merta M, Tesar V, Zima T, Jirsa M, Rysava R, Zabka J. Cytokine profile in autosomal dominant polycystic kidney disease. Biochem Mol Biol Int 1997;41:619-624.
28. Luo Y, Jiang D, Wen D, Yang J, Li L. Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin. Heart Vessels 2004;19:257-262.
29. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-1566.
30. Doo YC, Han SJ, Han SW, Park WJ, Choi SH, Cho GY, Hong KS, Han KR, Lee NH, Oh DJ, Ryu KH, Rim CY, Lee KH, Lee Y. Effect of preexisting statin use on expression of C-reactive protein, adhesion molecules, interleukin-6, and antioxidized low-density lipoprotein antibody in patients with unstable angina undergoing coronary stenting. Clin Cardiol 2005;28:72-76.